<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S1359644621000489</prism:url><dc:identifier>doi:10.1016/j.drudis.2021.01.018</dc:identifier><eid>1-s2.0-S1359644621000489</eid><prism:doi>10.1016/j.drudis.2021.01.018</prism:doi><pii>S1359-6446(21)00048-9</pii><dc:title>An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads </dc:title><prism:publicationName>Drug Discovery Today</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>13596446</prism:issn><prism:volume>26</prism:volume><prism:issueIdentifier>5</prism:issueidentifier><prism:startingPage>1115</prism:startingpage><prism:endingPage>1125</prism:endingpage><prism:pageRange>1115-1125</prism:pagerange><prism:number>5</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2021-05-31</prism:coverdate><prism:coverDisplayDate>May 2021</prism:coverdisplaydate><prism:copyright>© 2021 Elsevier Ltd. All rights reserved.</prism:copyright><prism:publisher>Elsevier Ltd.</prism:publisher><dc:creator>Chaudhry, Charu</dc:creator><dc:creator>Tebben, Andrew</dc:creator><dc:creator>Tokarski, John S.</dc:creator><dc:creator>Borzilleri, Robert</dc:creator><dc:creator>Pitts, William J.</dc:creator><dc:creator>Lippy, Jonathan</dc:creator><dc:creator>Zhang, Litao</dc:creator><dc:description>
                  Kinases, accounting for 20% of the human genome, have been the focus of pharmaceutical drug discovery efforts for over three decades. Despite concerns surrounding the tractability of kinases as drug targets, it is evident that kinase drug discovery offers great potential, underscored by the US Food and Drug Administration (FDA) approval of 48 small-molecule kinase inhibitors. Despite these successes, it is challenging to identify novel kinome selective inhibitors with good pharmacokinetic/pharmacodynamic (PK/PD) properties, and resistance to kinase inhibitor treatment frequently arises. A new era of kinase drug discovery predicates the need for diverse and powerful tools to discover the next generation of kinase inhibitors. Here, we outline key tenets of the Bristol Meyers Squibb (BMS) kinase platform, to enable efficient generation of highly optimized kinase inhibitors.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><link href="https://api.elsevier.com/content/article/pii/S1359644621000489" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S1359644621000489" rel="scidir"/></link></coredata><objects><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="82" height="102" size="3751">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="89" height="80" size="3630">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="89" height="81" size="3639">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="391" size="72391">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="430" size="45346">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="425" size="74735">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="279" size="58585">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="470" size="59691">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="261" size="31695">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="458" size="33998">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="442" size="59337">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="131" height="163" size="17221">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="182" height="164" size="23318">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="179" height="164" size="23523">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="102" size="8430">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="5733">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="111" size="8208">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="73" size="4971">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="123" size="6905">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="68" size="4506">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="120" size="3967">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="116" size="7597">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="363" height="453" size="44387">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="394" height="355" size="33752">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="394" height="360" size="37971">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1731" size="563587">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1905" size="331775">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1884" size="611721">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1236" size="511541">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="2080" size="485107">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1155" size="245807">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="2028" size="257058">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1960" size="471955">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1542540">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621000489-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85103369173</scopus-id><scopus-eid>2-s2.0-85103369173</scopus-eid><pubmed-id>33497831</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85103369173" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271275</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291727</xocs:ssid>
         <xocs:ssid type="subj">291850</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>Drug Discovery Today</xocs:srctitle>
      <xocs:normalized-srctitle>DRUGDISCOVERYTODAY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20210123">2021-01-23</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20210123">2021-01-23</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20210609">2021-06-09</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20210609">2021-06-09</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-06-09T12:52:12</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S1359644621000489</xocs:eid>
      <xocs:pii-formatted>S1359-6446(21)00048-9</xocs:pii-formatted>
      <xocs:pii-unformatted>S1359644621000489</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.drudis.2021.01.018</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S1359644621X00062</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210609">2021-06-09T12:34:09.117838Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20210501</xocs:date-search-begin>
      <xocs:date-search-end>20210531</xocs:date-search-end>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1611419742">2021-01-23T16:35:42.101849Z</xocs:indexeddate>
      <xocs:articleinfo>articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure body acknowledge affil articletitle auth authfirstini authfull authlast footnotes orcid primabst pubtype ref teaserabst vitae</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>1359-6446</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>13596446</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>26</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>26</xocs:volume>
      </xocs:volume-list>
      <xocs:iss-first>5</xocs:iss-first>
      <xocs:issue-list>
         <xocs:issue>5</xocs:issue>
      </xocs:issue-list>
      <xocs:vol-iss-suppl-text>Volume 26, Issue 5</xocs:vol-iss-suppl-text>
      <xocs:sort-order>5</xocs:sort-order>
      <xocs:first-fp>1115</xocs:first-fp>
      <xocs:last-lp>1125</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>1115</xocs:first-page>
         <xocs:last-page>1125</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>202105</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>May 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-05-01</xocs:cover-date-start>
      <xocs:cover-date-end>2021-05-31</xocs:cover-date-end>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>REVIEWS</xocs:hub-sec-title>
         <xocs:hub-sec>
            <xocs:hub-sec-title>Keynote</xocs:hub-sec-title>
         </xocs:hub-sec>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>© 2021 Elsevier Ltd. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>INNOVATIVEKINOMEPLATFORMACCELERATESMALLMOLECULEINHIBITORDISCOVERYOPTIMIZATIONHITSLEADS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>CHAUDHRY</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>C</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Evolving beyond a Type I ATP site inhibitor</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Building a flexible kinase hits-to-leads platform</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Kinome-wide profiling</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Mechanism toolbox</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Case studies from hits to leads</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Biochemical triage: RIPK3</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Crucial role of inhibitor binding kinetics in lead optimization: TGFβR and BTK</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Bringing it full circle: chemogenomics screen to the clinic: TYK2</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Concluding remarks and outlook</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Declaration of interests</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sbref0005">
            <xocs:ref-normalized-surname>FERGUSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>353</xocs:ref-first-fp>
            <xocs:ref-last-lp>377</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0010">
            <xocs:ref-normalized-surname>ROSKOSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>19</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0015">
            <xocs:ref-normalized-surname>NAGAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>4236</xocs:ref-first-fp>
            <xocs:ref-last-lp>4243</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0020">
            <xocs:ref-normalized-surname>NAKANO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>17</xocs:ref-first-fp>
            <xocs:ref-last-lp>26</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0025">
            <xocs:ref-normalized-surname>YUN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>217</xocs:ref-first-fp>
            <xocs:ref-last-lp>227</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0030">
            <xocs:ref-normalized-surname>TAKEUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1774</xocs:ref-first-fp>
            <xocs:ref-last-lp>1780</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0035">
            <xocs:ref-normalized-surname>TRAYNOR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>2120</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0040">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>422</xocs:ref-first-fp>
            <xocs:ref-last-lp>439</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0045">
            <xocs:ref-normalized-surname>COHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>96</xocs:ref-first-fp>
            <xocs:ref-last-lp>104</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0050">
            <xocs:ref-normalized-surname>FICARRO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>301</xocs:ref-first-fp>
            <xocs:ref-last-lp>305</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0055">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0060">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>111</xocs:ref-first-fp>
            <xocs:ref-last-lp>137</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0065">
            <xocs:ref-normalized-surname>SUN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>465</xocs:ref-first-fp>
            <xocs:ref-last-lp>474</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0070">
            <xocs:ref-normalized-surname>DAVIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1046</xocs:ref-first-fp>
            <xocs:ref-last-lp>1051</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0075">
            <xocs:ref-normalized-surname>MANNING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>1912</xocs:ref-first-fp>
            <xocs:ref-last-lp>1934</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0080">
            <xocs:ref-normalized-surname>KNIGHTON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1991</xocs:ref-pub-year>
            <xocs:ref-first-fp>407</xocs:ref-first-fp>
            <xocs:ref-last-lp>414</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0085">
            <xocs:ref-normalized-surname>TONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>190</xocs:ref-first-fp>
            <xocs:ref-last-lp>200</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0090">
            <xocs:ref-normalized-surname>COWANJACOB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>541</xocs:ref-first-fp>
            <xocs:ref-last-lp>561</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0095">
            <xocs:ref-normalized-surname>COX</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>29</xocs:ref-first-fp>
            <xocs:ref-last-lp>43</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0100">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>8</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0105">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>94</xocs:ref-first-fp>
            <xocs:ref-last-lp>104</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0110">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>733</xocs:ref-first-fp>
            <xocs:ref-last-lp>740</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0115">
            <xocs:ref-normalized-surname>LEVITZKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>462</xocs:ref-first-fp>
            <xocs:ref-last-lp>469</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0120">
            <xocs:ref-normalized-surname>MULLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>818</xocs:ref-first-fp>
            <xocs:ref-last-lp>821</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0125">
            <xocs:ref-normalized-surname>DEGORCE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>22</xocs:ref-first-fp>
            <xocs:ref-last-lp>32</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0130">
            <xocs:ref-normalized-surname>BRANCA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>639</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0135">
            <xocs:ref-normalized-surname>SWINNEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>801</xocs:ref-first-fp>
            <xocs:ref-last-lp>808</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0140">
            <xocs:ref-normalized-surname>SWINNEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>507</xocs:ref-first-fp>
            <xocs:ref-last-lp>519</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0145">
            <xocs:ref-normalized-surname>KNIGHT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>621</xocs:ref-first-fp>
            <xocs:ref-last-lp>637</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0150">
            <xocs:ref-normalized-surname>COPELAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>87</xocs:ref-first-fp>
            <xocs:ref-last-lp>95</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0155">
            <xocs:ref-normalized-surname>COPELAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>730</xocs:ref-first-fp>
            <xocs:ref-last-lp>739</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0160">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>488</xocs:ref-first-fp>
            <xocs:ref-last-lp>496</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0165">
            <xocs:ref-normalized-surname>TUMMINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>5481</xocs:ref-first-fp>
            <xocs:ref-last-lp>5492</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0170">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>17</xocs:ref-first-fp>
            <xocs:ref-last-lp>37</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0175">
            <xocs:ref-normalized-surname>VASTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>206</xocs:ref-first-fp>
            <xocs:ref-last-lp>214</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0180">
            <xocs:ref-normalized-surname>ROBERS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>10091</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0185">
            <xocs:ref-normalized-surname>HART</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>266</xocs:ref-first-fp>
            <xocs:ref-last-lp>271</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0190">
            <xocs:ref-normalized-surname>LU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>467</xocs:ref-first-fp>
            <xocs:ref-last-lp>474</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0195">
            <xocs:ref-normalized-surname>HARIKRISHNAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1026</xocs:ref-first-fp>
            <xocs:ref-last-lp>1034</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0200">
            <xocs:ref-normalized-surname>WATTERSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>9173</xocs:ref-first-fp>
            <xocs:ref-last-lp>9200</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0205">
            <xocs:ref-normalized-surname>WATTERSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>3228</xocs:ref-first-fp>
            <xocs:ref-last-lp>3250</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0210">
            <xocs:ref-normalized-surname>TOKARSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>11061</xocs:ref-first-fp>
            <xocs:ref-last-lp>11174</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0215">
            <xocs:ref-normalized-surname>MOSLIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>8953</xocs:ref-first-fp>
            <xocs:ref-last-lp>8972</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0220">
            <xocs:ref-normalized-surname>WROBLESKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>8973</xocs:ref-first-fp>
            <xocs:ref-last-lp>8995</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0225">
            <xocs:ref-normalized-surname>MURPHY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>61</xocs:ref-first-fp>
            <xocs:ref-last-lp>67</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0230">
            <xocs:ref-normalized-surname>BITENCOURTFERREIRA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>253</xocs:ref-first-fp>
            <xocs:ref-last-lp>265</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0235">
            <xocs:ref-normalized-surname>YOUNG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>167</xocs:ref-first-fp>
            <xocs:ref-last-lp>190</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0240">
            <xocs:ref-normalized-surname>SCHAPIRA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>949</xocs:ref-first-fp>
            <xocs:ref-last-lp>963</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>CHAUDHRYX2021X1115</xocs:refkey3>
         <xocs:refkey4lp>CHAUDHRYX2021X1115X1125</xocs:refkey4lp>
         <xocs:refkey4ai>CHAUDHRYX2021X1115XC</xocs:refkey4ai>
         <xocs:refkey5>CHAUDHRYX2021X1115X1125XC</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-06-09T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-06-09T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2021 Elsevier Ltd. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2021-04-05T22:51:24.953Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp-car</xocs:funding-addon-type>
         <xocs:funding-text>We would like to thank Amy Hart, Steve Wrobleski, Scott Watterson, and Ryan Moslin for critical reading of the manuscript. Special thanks to Julia Heinrich for kinase patent literature search support, Mingyi Liu for bioinformatic support, Ramesh Padmanabha for kinome panel quality control, Gretchen Schroeder for initial probe synthesis, and Hao Lu and Lynn Abell for contributions to hit triage toolbox and kinetics toolbox. Special thanks to the kinase working groups, as well as the kinome, cellular technologies, and data management and analytics teams for assay and data support.</xocs:funding-text>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S1359-6446(21)00048-9</xocs:pii-formatted>
         <xocs:pii-unformatted>S1359644621000489</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S1359644621000489</xocs:eid>
         <xocs:doi>10.1016/j.drudis.2021.01.018</xocs:doi>
         <xocs:cid>271275</xocs:cid>
         <xocs:timestamp>2021-06-09T11:56:16.044566Z</xocs:timestamp>
         <xocs:cover-date-start>2021-05-01</xocs:cover-date-start>
         <xocs:cover-date-end>2021-05-31</xocs:cover-date-end>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/MAIN/application/pdf/2b93060f0a6461bf00055d9fd373e698/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2199796</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>11</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S1359644621000489-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/PREVIEW/image/png/e10f128fd304d1805f49bb509c8cf544/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>83249</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/fx1/DOWNSAMPLED/image/jpeg/6cd92a2e5c3824f8311ec34105315c9c/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3751</xocs:filesize>
               <xocs:pixel-height>102</xocs:pixel-height>
               <xocs:pixel-width>82</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/fx2/DOWNSAMPLED/image/jpeg/e598dff1f81d3ce6839ab7a81ff13482/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3630</xocs:filesize>
               <xocs:pixel-height>80</xocs:pixel-height>
               <xocs:pixel-width>89</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/fx3/DOWNSAMPLED/image/jpeg/b61b0430f7f6bb1b9d116651204248cf/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3639</xocs:filesize>
               <xocs:pixel-height>81</xocs:pixel-height>
               <xocs:pixel-width>89</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr1/DOWNSAMPLED/image/jpeg/1d9311f9bb5d429552e5d23371d1e4a2/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>72391</xocs:filesize>
               <xocs:pixel-height>391</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr2/DOWNSAMPLED/image/jpeg/9a6df3bb6c8eaaad97bc5eb27b55dba3/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>45346</xocs:filesize>
               <xocs:pixel-height>430</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr3/DOWNSAMPLED/image/jpeg/61020346cf990629ca933b8bff48edd9/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>74735</xocs:filesize>
               <xocs:pixel-height>425</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr4/DOWNSAMPLED/image/jpeg/45a346a6546807f282408185588ada76/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>58585</xocs:filesize>
               <xocs:pixel-height>279</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr5/DOWNSAMPLED/image/jpeg/5144581747e52c8fba6c01f2186ecf15/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>59691</xocs:filesize>
               <xocs:pixel-height>470</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr6/DOWNSAMPLED/image/jpeg/4c70a973e259b56222129b5bd18961e2/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31695</xocs:filesize>
               <xocs:pixel-height>261</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr7/DOWNSAMPLED/image/jpeg/ce8a0ec77502fe470ed3541457a6f6b7/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33998</xocs:filesize>
               <xocs:pixel-height>458</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr8/DOWNSAMPLED/image/jpeg/584dd96d727e1b43f67b8091a1a0ce08/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>59337</xocs:filesize>
               <xocs:pixel-height>442</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/fx1/THUMBNAIL/image/gif/af9eb1e0b3808927da94e232cd09026b/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>17221</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>131</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/fx2/THUMBNAIL/image/gif/9690b05a2480fa4512aea3a8002b0cb4/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>23318</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>182</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/fx3/THUMBNAIL/image/gif/37a469e47284efc994956d477e4bc660/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>23523</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>179</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr1/THUMBNAIL/image/gif/776a3b32c6d8cba3238f6c677d6ad487/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8430</xocs:filesize>
               <xocs:pixel-height>102</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr2/THUMBNAIL/image/gif/bbb3d9f04e83aaaef59842b5def63298/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5733</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr3/THUMBNAIL/image/gif/792166438f94c19bffd029c2daa71cbd/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8208</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr4/THUMBNAIL/image/gif/b9fdbb06a550f4519238001601eaeba7/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4971</xocs:filesize>
               <xocs:pixel-height>73</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr5/THUMBNAIL/image/gif/e984f7888a7e60f8a72f9c88ada25171/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6905</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr6/THUMBNAIL/image/gif/3a706858a83d6db0107da7e59ccceaa6/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4506</xocs:filesize>
               <xocs:pixel-height>68</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr7/THUMBNAIL/image/gif/e4d4d5de8d27ee94a84f85d84a23e252/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3967</xocs:filesize>
               <xocs:pixel-height>120</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr8/THUMBNAIL/image/gif/e8dd6fa7c498890f6c1e59f813376390/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7597</xocs:filesize>
               <xocs:pixel-height>116</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/fx1/HIGHRES/image/jpeg/50f6d1b3686c77d884613d1b2ce6465d/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>44387</xocs:filesize>
               <xocs:pixel-height>453</xocs:pixel-height>
               <xocs:pixel-width>363</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/fx2/HIGHRES/image/jpeg/89895eb51193ba8d22a4aa5149b2540c/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33752</xocs:filesize>
               <xocs:pixel-height>355</xocs:pixel-height>
               <xocs:pixel-width>394</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/fx3/HIGHRES/image/jpeg/8229999adb2fae7df16a2a65400b920f/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37971</xocs:filesize>
               <xocs:pixel-height>360</xocs:pixel-height>
               <xocs:pixel-width>394</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr1/HIGHRES/image/jpeg/22902a7ee6dd380d86263715e839cf83/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>563587</xocs:filesize>
               <xocs:pixel-height>1731</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr2/HIGHRES/image/jpeg/9f33840832035cb68d9b4053fcab168f/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>331775</xocs:filesize>
               <xocs:pixel-height>1905</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr3/HIGHRES/image/jpeg/4387e255c4b2ea1d9485b318f29ae825/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>611721</xocs:filesize>
               <xocs:pixel-height>1884</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr4/HIGHRES/image/jpeg/5eaf74072594df60423e13fb6cf3c89c/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>511541</xocs:filesize>
               <xocs:pixel-height>1236</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr5/HIGHRES/image/jpeg/89e6343fdfe1c080c9dc9e3336c2d0af/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>485107</xocs:filesize>
               <xocs:pixel-height>2080</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr6/HIGHRES/image/jpeg/6e2752b96b165d601d5fa0cbbfe4043f/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>245807</xocs:filesize>
               <xocs:pixel-height>1155</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr7/HIGHRES/image/jpeg/bca3465887afefe9990931bd16f672d6/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>257058</xocs:filesize>
               <xocs:pixel-height>2028</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621000489/gr8/HIGHRES/image/jpeg/52a6ea00d9c62bd7e26be2a0a01242cf/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>471955</xocs:filesize>
               <xocs:pixel-height>1960</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621000489-am.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10LX9MG07RZ/MAIN/application/pdf/d49247fa2d35b623ed49c72de33fc4c2/am.pdf</xocs:ucs-locator>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>1542540</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" version="5.5" xml:lang="en" docsubtype="rev">
         <item-info>
            <jid>DRUDIS</jid>
            <aid>2909</aid>
            <ce:pii>S1359-6446(21)00048-9</ce:pii>
            <ce:doi>10.1016/j.drudis.2021.01.018</ce:doi>
            <ce:copyright type="full-transfer" year="2021">Elsevier Ltd</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig0005">
               <ce:label>Figure 1</ce:label>
               <ce:caption id="cap0005">
                  <ce:simple-para id="spar0005" view="all">Canonical kinase catalytic domain structure and inhibitor binding modes. Structural overview of a kinase catalytic domain. The protein kinase is shown as ribbons, and the main regulatory elements are marked: the hinge region connecting the N- and the C-loops in magenta; the activation loop colored in red, including the Asp-Phe-Gly (DFG) motif, the P-loop in yellow, and the α-C-helix represented in blue with ATP carbons in gray. The insets highlight the binding modes for type I–IV inhibitors, with the inhibitors shown as sticks with carbon atoms in light blue. ATP, Type I/II kinase inhibitors have one to three hydrogen bond interactions with the hinge residues and extend into various pockets nearby (not highlighted here); type I inhibitors (e.g., tofacitinib/JAK1, 3EYG) bind to the active conformation of the kinase with the aspartate residue of the DFG motif pointing into the ATP-binding pocket; type II inhibitors e.g., imatinib/c-Abl1, 1IEP) bind and stabilize an inactive conformation of the kinase with the flipped aspartate residue facing outward of the binding pocket. Type III inhibitors (e.g., refametinib/MEK1, 3E8N) occupy an allosteric pocket that is adjacent to the ATP-binding pocket but does not overlap with it; type IV inhibitors (e.g. asciminib/Abl1, 5MO4) bind to an allosteric pocket remote from the ATP-binding pocket.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0005" role="short">Figure 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S1359644621000489/gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0010">
               <ce:label>Figure 2</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="spar0010" view="all">US Food and Drug Administration (FDA)-approved small-molecule kinase inhibitors (Cortellis). Type I, II, and III inhibitors are indicated in green, orange, and blue, respectively; irreversible inhibitors are indicated in yellow; and lipid kinase inhibitors in purple <ce:cross-ref id="crf0005" refid="bib0010">[2]</ce:cross-ref>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0010" role="short">Figure 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S1359644621000489/gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0015">
               <ce:label>Figure 3</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="spar0015" view="all">Evolution of the Bristol Myers Squibb (BMS) kinome platform for parallel kinome-wide profiling and high-throughput mechanism studies. Key innovations are highlighted, including promiscuous probe scaffold design, novel assay technologies, process workflow, mechanistic toolbox, and data analytics. Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0015" role="short">Figure 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S1359644621000489/gr3" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0020">
               <ce:label>Figure 4</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="spar0020" view="all">Comprehensive Kinase Mechanistic Platform Enables Differentiation of Diverse Inhibitor Mechanisms.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0020" role="short">Figure 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S1359644621000489/gr4" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0025">
               <ce:label>Figure 5</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="spar0025" view="all">
                     <ce:bold>(a)</ce:bold> Mechanistic triage to differentiate chemotypes at HTS stage. <ce:bold>(b)</ce:bold> Analysis of high-throughput time dependence studies in the HTS highlighting compounds in the yellow box (44) with a shift of ≥5 in the RIPK3 IC50 at 5 and 60<ce:hsp sp="0.25"/></ce:hsp>min. <ce:bold>(c)</ce:bold> Analysis of high-throughput MOI studies in the HTS. Yellow box highlights compounds with a shift of less than 5 in RIPK3 IC50 between low and high probe concentrations. <ce:bold>(d)</ce:bold> HTS hit from the mechanistic triage.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0025" role="short">Figure 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S1359644621000489/gr5" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0030">
               <ce:label>Figure 6</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="spar0030" view="all">Residence time as a key parameter in lead optimization. Structure–kinetic relationship in TGFβR1 highlighting key interaction of hydrogen bond with Asp 351 in backpocket of pyrolopyrimidine Compound <ce:bold>3 (a)</ce:bold> that drives long residence time and increased cellular potency vs pyrolotriazine Compound <ce:bold>2</ce:bold> which lacks this interaction <ce:bold>(b)</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0030" role="short">Figure 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S1359644621000489/gr6" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0035">
               <ce:label>Figure 7</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="spar0035" view="all">Inactivation kinetics for lead BTK irreversible inhibitors. <ce:bold>(a)</ce:bold> Time-dependent irreversible inhibition reaction; <ce:bold>(b)</ce:bold> inactivation kinetics characterization of ibrutinib and branebrutinib.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0035" role="short">Figure 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S1359644621000489/gr7" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0040">
               <ce:label>Figure 8</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="spar0040" view="all">Discovery and optimization of a Type IV allosteric kinase inhibitor. <ce:bold>(a)</ce:bold> Schematic representation of the four domains comprising the protein structure of TYK2: the N-terminal FERM domain which mediates stable association of JAKs with receptor domains, the Src homology2 SH2 domain involved in receptor binding, JH2 pseudokinase domain with a canonical kinase fold that lacks catalytic function despite binding ATP and is important for regulating activity of the kinase domain, and the JH1 C terminal catalytically active kinase domain. <ce:bold>(b)</ce:bold> Profiles of classical Type I in-house JH1 inhibitor (Compound <ce:bold>6</ce:bold>) and allosteric Type IV JH2 selective compound (Compound <ce:bold>7</ce:bold>) in biochemical HTRF binding displacement assays using proprietary ATP binding site probes. <ce:bold>(c)</ce:bold> Correlation between potency against Tyk2 pseudokinase domain as measured by HTRF displacement versus human whole blood potency. <ce:bold>(d)</ce:bold> Crystal structure of the Tyk2 pseudokinase domain, ribbon representation, with bound JH2 selective lead Compound <ce:bold>7</ce:bold> shown in stick representation. The pyridazine <ce:italic>N</ce:italic>-methylamide provides potency and selectivity by making key interactions to the hinge region of JH2 and the Ala961 pocket; cyclopropylamide occupies the extended hinge region; triazole moiety also displaces structural water and forms key H-bond to Arg 738; C2′ methoxy orients near Lys and occupies the C-terminal lobe pocket.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0040" role="short">Figure 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S1359644621000489/gr8" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
         </ce:floats>
         <head>
            <ce:dochead id="doh0005">
               <ce:textfn>Review</ce:textfn>
               <ce:dochead id="doh0010">
                  <ce:textfn>Keynote</ce:textfn>
               </ce:dochead>
            </ce:dochead>
            <ce:title id="tit0005">An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads</ce:title>
            <ce:author-group id="aug0005">
               <ce:author id="aut0005" biographyid="vt0005" orcid="0000-0002-4308-633X" author-id="S1359644621000489-91cc51001cf980a3fcbdf118787c2c47">
                  <ce:given-name>Charu</ce:given-name>
                  <ce:surname>Chaudhry</ce:surname>
                  <ce:cross-ref id="crf0010" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0015" refid="fn0005">
                     <ce:sup loc="post">‡</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0020" refid="cor0005">
                     <ce:sup loc="post">⁎</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="aut0010" author-id="S1359644621000489-f9390aa7c64e75882f4fa4b9bf851f69">
                  <ce:given-name>Andrew</ce:given-name>
                  <ce:surname>Tebben</ce:surname>
                  <ce:cross-ref id="crf0025" refid="aff0010">
                     <ce:sup loc="post">2</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0015" orcid="0000-0001-6835-6845" author-id="S1359644621000489-9f238f08aca282c84f27b25ffcd6b3de">
                  <ce:given-name>John S.</ce:given-name>
                  <ce:surname>Tokarski</ce:surname>
                  <ce:cross-ref id="crf0030" refid="aff0010">
                     <ce:sup loc="post">2</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0020" author-id="S1359644621000489-7006faa32a8f19a0f0c27758b6cdd3f8">
                  <ce:given-name>Robert</ce:given-name>
                  <ce:surname>Borzilleri</ce:surname>
                  <ce:cross-ref id="crf0035" refid="aff0015">
                     <ce:sup loc="post">3</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0025" author-id="S1359644621000489-c0f47a3a2b8577256106644d81524f07">
                  <ce:given-name>William J.</ce:given-name>
                  <ce:surname>Pitts</ce:surname>
                  <ce:cross-ref id="crf0040" refid="aff0020">
                     <ce:sup loc="post">4</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0030" biographyid="vt0010" author-id="S1359644621000489-cc5be0c3ab5138ab70a8c61db73cb26f">
                  <ce:given-name>Jonathan</ce:given-name>
                  <ce:surname>Lippy</ce:surname>
                  <ce:cross-ref id="crf0045" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0050" refid="fn0005">
                     <ce:sup loc="post">‡</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0035" biographyid="vt0015" author-id="S1359644621000489-7d5ae8fdab252548d6552c03210c6bac">
                  <ce:given-name>Litao</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crf0055" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0060" refid="fn0005">
                     <ce:sup loc="post">‡</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:affiliation id="aff0005" affiliation-id="S1359644621000489-b06af3f5f1a437f5b795b1d0347ef912">
                  <ce:label>1</ce:label>
                  <ce:textfn>Lead Discovery and Optimization, Bristol Myers Squibb, NJ, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Lead Discovery and Optimization</sa:organization>
                     <sa:organization>Bristol Myers Squibb</sa:organization>
                     <sa:state>NJ</sa:state>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff0010" affiliation-id="S1359644621000489-6958941f3204629ca74a4245ad8adbbb">
                  <ce:label>2</ce:label>
                  <ce:textfn>Molecular Structure and Design, Molecular Discovery Technologies, Bristol Myers Squibb, NJ, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Molecular Structure and Design</sa:organization>
                     <sa:organization>Molecular Discovery Technologies</sa:organization>
                     <sa:organization>Bristol Myers Squibb</sa:organization>
                     <sa:state>NJ</sa:state>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff0015" affiliation-id="S1359644621000489-64628441e91cb3d556493ea937258df6">
                  <ce:label>3</ce:label>
                  <ce:textfn>Oncology Discovery Chemistry, Bristol Myers Squibb, NJ, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Oncology Discovery Chemistry</sa:organization>
                     <sa:organization>Bristol Myers Squibb</sa:organization>
                     <sa:state>NJ</sa:state>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff0020" affiliation-id="S1359644621000489-7535b1801937ed3c356d95558a617c95">
                  <ce:label>4</ce:label>
                  <ce:textfn>Immunosciences Discovery Chemistry, Bristol Myers Squibb, NJ, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Immunosciences Discovery Chemistry</sa:organization>
                     <sa:organization>Bristol Myers Squibb</sa:organization>
                     <sa:state>NJ</sa:state>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor0005">
                  <ce:label>⁎</ce:label>
                  <ce:text>
                     <ce:italic>Corresponding author</ce:italic>:</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn0005">
                  <ce:label>‡</ce:label>
                  <ce:note-para id="npar0005" view="all">Current address: Discovery Technologies Molecular Pharmacology, Janssen Research and Development, LLC, Spring House, PA, USA.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:abstract id="abs0005" view="all" class="author"><ce:abstract-sec id="abst0005" view="all">
                  <ce:simple-para id="spar0045" view="all">Kinases, accounting for 20% of the human genome, have been the focus of pharmaceutical drug discovery efforts for over three decades. Despite concerns surrounding the tractability of kinases as drug targets, it is evident that kinase drug discovery offers great potential, underscored by the US Food and Drug Administration (FDA) approval of 48 small-molecule kinase inhibitors. Despite these successes, it is challenging to identify novel kinome selective inhibitors with good pharmacokinetic/pharmacodynamic (PK/PD) properties, and resistance to kinase inhibitor treatment frequently arises. A new era of kinase drug discovery predicates the need for diverse and powerful tools to discover the next generation of kinase inhibitors. Here, we outline key tenets of the Bristol Meyers Squibb (BMS) kinase platform, to enable efficient generation of highly optimized kinase inhibitors.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract id="abs0010" class="teaser" view="all">
               <ce:section-title id="sect0005">Teaser</ce:section-title>
               <ce:abstract-sec id="abst0010" view="all">
                  <ce:simple-para id="spar0050" view="all">This review highlights the evolving kinase small-molecule drug discovery landscape, and key tenets of the kinase platform at Bristol Myers Squibb to discover the next generation of kinase inhibitors.</ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec0005" role="introduction" view="all">
                  <ce:section-title id="sect0010">Introduction</ce:section-title>
                  <ce:para id="par0005" view="all">Signal transduction mediated by kinase-dependent phosphotransfer cascades is involved in nearly all biological pathways. Given their crucial roles, kinases provide multiple nodes for therapeutic intervention, making them one of the most intensely pursued target classes in the pharmaceutical industry <ce:cross-ref id="crf0065" refid="bib0005">[1]</ce:cross-ref>. Although ∼20% of drug discovery efforts worldwide are directed at the protein kinase superfamily, there are to date only 48 approved kinase drugs <ce:cross-ref id="crf0070" refid="bib0010">[2]</ce:cross-ref>. Notably, the landmark approval of imatinib, the first marketed kinase drug, came in 2001 <ce:cross-ref id="crf0075" refid="bib0015">[3]</ce:cross-ref>, 20 years after the discovery of staurosporin, the first nonselective kinase inhibitor <ce:cross-ref id="crf0080" refid="bib0020">[4]</ce:cross-ref>. This was followed by the discovery of the first selective epidermal growth factor receptor (EGFR) marketed drugs, gefitinib and erlotinib, in 2004 for cancer, including pancreatic and nonsmall cell lung cancer <ce:cross-refs id="crfs0005" refid="bib0025 bib0030">[5,6]</ce:cross-refs>. Tofacitinib, a pan-Janus kinase (JAK) inhibitor was the first non-oncology kinase inhibitor to be approved, in 2012, for the treatment of rheumatoid arthritis <ce:cross-ref id="crf0085" refid="bib0035">[7]</ce:cross-ref>. Notably, current kinase inhibitors focus on only a small subset of the human kinome. Of the 48 approved drugs, 25 inhibit receptor protein tyrosine kinases, whereas ten inhibit nonreceptor protein-tyrosine kinases, and 13 are directed at protein-serine/threonine protein kinases; at least 18 of these drugs are also multikinase inhibitors. Additionally, the data also indicate that most of these are directed toward oncology, whereas seven of the FDA-approved kinase inhibitors are directed toward inflammatory, transplantation, and autoimmune diseases <ce:cross-refs id="crfs0010" refid="bib0010 bib0040">[2,8]</ce:cross-refs>. There is a large fraction of the kinome that is untapped, the ‘dark kinome’, for which new tools are needed to investigate unknown functions in the pathogenesis of currently untargeted diseases in non-oncology therapeutic areas. Currently ∼244 protein kinases have been mapped to disease loci, and 175 different orally effective protein kinase inhibitors are in Phase I-II clinical trials worldwide (Clarivate Analytics: Cortellius) <ce:cross-ref id="crf0090" refid="bib0010">[2]</ce:cross-ref>. Thus, the kinase field is still rapidly evolving.</ce:para>
                  <ce:para id="par0010" view="all">Drugging kinases has proven to be challenging for two main reasons. First, similarities between the ATP-binding pockets of 500+ kinases made it appear impossible to develop selective compounds. Second, designing compounds with the required potency to compete with millimolar ATP concentrations in the cell appeared unsurmountable. Consequently, kinase inhibitors suffer from a high attrition rate <ce:cross-ref id="crf0095" refid="bib0045">[9]</ce:cross-ref>, ascribed to nontransferrable efficacy (i.e., efficacy that does not translate from <ce:italic>in vitro</ce:italic> to <ce:italic>in vivo</ce:italic>) and mechanistic toxicity issues for ATP-competitive inhibitors.</ce:para>
                  <ce:para id="par0015" view="all">These challenges also provide opportunities for growth and innovation in the kinase small-molecule drug discovery space. Given the size of the kinome and the potential therapeutic impact, there is a continual need for the development of new technologies to enable rapid discovery and optimization of compounds that serve both as pharmacological target validation tools and as lead compounds for medicinal chemistry <ce:cross-refs id="crfs0015" refid="bib0045 bib0050 bib0055 bib0060 bib0065">[9–13]</ce:cross-refs>. For example, it is anticipated that a much larger number of scaffolds, chemotypes, and pharmacophores will be developed going forward with the advent of newer templated libraries and nanosynthesis techniques. Exploring more diversified kinase inhibitor scaffolds is crucial to deliver more shots on goal for improved success in the clinic. <ce:cross-ref id="crf0100" refid="fig0005">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig0005"/></ce:float-anchor> details the different kinase inhibitor types based on binding mode, and <ce:cross-ref id="crf0105" refid="fig0010">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig0010"/></ce:float-anchor> captures the distribution of approved kinase small-molecule inhibitors based on this classification <ce:cross-ref id="crf0110" refid="bib0010">[2]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0020" view="all">In this review, we outline the evolution of the BMS kinome platform for both high-throughput (HT) kinome-wide profiling and mechanistic characterization, highlight case studies from hit identification to lead optimization, and present a forward-looking vision for kinase inhibitor discovery. Three main areas are discussed: pharmacologically relevant hit identification and hit assessment; parallel structure–activity (SAR) and structure–liability (SLR) relationship panel screening; the mechanism toolbox and HT mechanistic case studies with broad kinome-wide applicability.</ce:para>
               </ce:section>
               <ce:section id="sec0010" view="all">
                  <ce:section-title id="sect0015">Evolving beyond a Type I ATP site inhibitor</ce:section-title>
                  <ce:para id="par0025" view="all">Despite diversity in primary amino acid sequence, protein kinases share a significant degree of similarity in their 3D structures, especially in their conserved catalytical domain, which houses the ATP-binding pocket <ce:cross-refs id="crfs0020" refid="bib0015 bib0070 bib0075">[3,14,15]</ce:cross-refs>. The catalytic domain comprises a β-sheet containing N-terminal lobe (N-lobe), an α-helical C-terminal lobe (C-lobe), and a connecting hinge region <ce:cross-ref id="crf0115" refid="bib0080">[16]</ce:cross-ref>; ATP binds in the cleft formed between the N- and C-lobes and most kinase inhibitors perturb ATP binding through interactions with this region <ce:cross-ref id="crf0120" refid="bib0085">[17]</ce:cross-ref>. A flexible activation loop starting with a conserved Asp-Phe-Gly (DFG) amino acid sequence controls access to the ATP-binding active site.</ce:para>
                  <ce:para id="par0030" view="all">The pharmaceutical industry has developed a nomenclature of kinase inhibitor type based on conformation of the binding pocket and mechanism of action <ce:cross-refs id="crfs0025" refid="bib0040 bib0090">[8,18]</ce:cross-refs>. Type I inhibitors are ATP competitive and often bind to the active (‘DFG-in’) conformation of the kinase with the Mg<ce:sup loc="post">2+</ce:sup> bound aspartate residue of the DFG motif facing into the active site. Type II inhibitors bind to an inactive conformation of a kinase, frequently with the aspartate residue of the DFG motif protruding outward from the ATP-binding site of the kinase; many type II inhibitors exploit specific pockets accessible in a region adjacent to the ATP-binding site because of the rotation of the DFG motif and/or α-C helix. Type III (‘allosteric’) inhibitors bind exclusively in an allosteric pocket adjacent to ATP. They can still be competitive with ATP because of stabilization of an inactive conformation, which is not compatible with ATP binding, but some are not competitive and can even bind preferentially to the ATP-bound form of the kinase. By contrast, type IV inhibitors bind to an allosteric site remote from the ATP-binding pocket <ce:cross-ref id="crf0125" refid="bib0095">[19]</ce:cross-ref>. They often bind to an interaction partner of the kinase, preventing the appropriate regulation, activation, or downstream action of the kinase. <ce:cross-ref id="crf0130" refid="fig0005">Fig. 1</ce:cross-ref> depicts structural differences in the binding of inhibitor types I–IV. The identification of non-ATP site-targeting (‘allosteric’) inhibitors is a potential avenue to overcome selectivity challenges. Irreversible kinase inhibitors bind covalently with a reactive nucleophilic cysteine residue proximal to the ATP-binding site, resulting in the blockage of the ATP site and irreversible inhibition, and most often are type I or type II inhibitors.</ce:para>
               </ce:section>
               <ce:section id="sec0015" view="all">
                  <ce:section-title id="sect0020">Building a flexible kinase hits-to-leads platform</ce:section-title>
                  <ce:para id="par0035" view="all">To address the challenges inherent to kinase drug discovery, BMS has built a comprehensive internal platform for parallel kinome-wide SAR/SLR and HT mechanism of action studies. Here, we describe the approach taken from 2003 to 2018 to implement and advance diverse technology platforms as a cornerstone of this strategy. These include assay technologies to measure accumulation of phosphorylated products and/or ADP formation/ATP depletion <ce:cross-ref id="crf0135" refid="bib0100">[20]</ce:cross-ref>. We initially deployed filtration assays utilizing radiolabeled ATP, considered the ‘gold standard’ for measuring kinase activity <ce:cross-ref id="crf0140" refid="bib0105">[21]</ce:cross-ref>. However, the low throughput and limited kinetic capability prompted investigation of alternative assay formats. The advent of Caliper microfluidic technology (Caliper Life Sciences, Hopkinton, MA, USA) in 2005, which monitors phosphorylation of fluorescently labeled peptide substrates, led to the growth of activity-based kinetic assays. In 2006, the first industrial Caliper robotic system was constructed, enabling 384-well miniaturization, increased sensitivity, and real-time kinetic and mechanistic readouts <ce:cross-ref id="crf0145" refid="bib0110">[22]</ce:cross-ref>. Between 2006 and 2012, the Caliper technology provided primary program support comprising up to 60 weekly SAR assays. During this time, it also became clear that successful kinase inhibitor discovery required parallel kinome-wide selectivity profiling with rapid data-turnaround times.</ce:para>
                  <ce:para id="par0040" view="all">Given that each of the available technologies had limitations and no commercially available system existed that addressed the breadth and scale of kinase drug discovery at BMS, we embarked on building our own internal platform. Building a comprehensive and adaptable platform to tackle increasingly complex kinase targets <ce:cross-refs id="crfs0030" refid="bib0115 bib0120">[23,24]</ce:cross-refs> based on newly emerging biology became a foundational principle for the BMS kinome platform. This platform was customized for portfolio needs focused on a rich diversity of targets and rapid data turnaround requirements to meet project milestones. <ce:cross-ref id="crf0150" refid="fig0015">Fig. 3</ce:cross-ref>
                     <ce:float-anchor refid="fig0015"/></ce:float-anchor> highlights some key advances in the evolution of our kinase technology platforms over the past decade.</ce:para>
                  <ce:section id="sec0020" view="all">
                     <ce:section-title id="sect0025">Kinome-wide profiling</ce:section-title>
                     <ce:para id="par0045" view="all">Faced with an expanding kinase discovery portfolio, developing internal capability for a HT, efficient, and cost-effective platform for driving in-parallel kinase program SAR and SLR relationships became an increasingly essential requirement to rapidly advance kinase hits to leads. In 2012, in a collaboration with the Computer-Assisted Drug Discovery and Discovery Chemistry groups, we designed and synthesized fluorescein-labeled ATP-competitive probes based on promiscuous kinase inhibitor scaffolds, which provided a signal for ∼80% of the kinome. With these probes in hand, we built a proprietary kinome-wide homogeneous time-resolved fluorescence resonance energy transfer (HTRF) <ce:cross-ref id="crf0155" refid="bib0125">[25]</ce:cross-ref> assay panel. Using internal technology capabilities, high-throughput streamlined methods were developed for kinome-wide HTRF probe identification and characterization, and binding competition assay development/validation in 1536-plate mode. These workflows enabled rapid panel expansion to ∼300 kinase SAR/SLR assays, covering ∼60% of the entire kinome, with significant cost reduction, increased flexibility, and weekly/biweekly data turnaround. To efficiently manage the large data sets produced by kinome profiling, custom information technology tools were developed to track assay performance and capture data into centralized databases, allowing multiparametric data analysis, kinome-wide data visualization, and pathway analysis.</ce:para>
                     <ce:para id="par0050" view="all">Application of kinome-wide profiling at an initial screening stage provides efficient annotation of all the potential kinase targets for a given chemotype, enabling not only selectivity profiling from a liability standpoint, but also data analysis, which can lead to the fortuitous discovery of tool compounds for other candidate targets (i.e., off-target cross-fertilization). These tool compounds enable chemical biology exploration of new biological hypotheses and target validation. This approach can also benefit indications where inhibition of a single kinase might not be sufficient to affect the disease process significantly <ce:cross-ref id="crf0160" refid="bib0130">[26]</ce:cross-ref>. Broad profiling also enables the identification of multitargeted kinase inhibitors, the inhibitory activity of which is focused on a small number of specific kinase targets. Chemotypes with specific inhibitory profiles are necessary to investigate the utility of target combinations in cellular and animal models.</ce:para>
                  </ce:section>
                  <ce:section id="sec0025" view="all">
                     <ce:section-title id="sect0030">Mechanism toolbox</ce:section-title>
                     <ce:para id="par0055" view="all">The gamut of kinase assay technologies has also enabled the development of a powerful mechanistic toolbox for thermodynamic and kinetic characterization of kinase–inhibitor interactions at various stages of hits-to-leads optimization. The driving force for a comprehensive mechanistic platform came from program needs at different stages from the initial HT screening (HTS) campaign and requirement for mechanistic triage, to SAR incorporating both binding affinity and kinetics, to building tools for biochemical–cellular connectivity. Thermodynamics represents an equilibrium static view and has been the primary force in drug discovery for the past decades, whereas kinetics captures a more dynamic view and recent mounting evidence has shown its crucial role in increasing the success of clinical outcomes <ce:cross-refs id="crfs0035" refid="bib0135 bib0140">[27,28]</ce:cross-refs>. Capability for HT affinity measurements and determination of mode of inhibition have been developed, and are especially crucial for kinase inhibitor potency in cells with high intracellular ATP concentrations <ce:cross-ref id="crf0165" refid="bib0145">[29]</ce:cross-ref>. Additionally, capabilities have been developed for HT measurement of residence time, a vital determinant of <ce:italic>in vivo</ce:italic> efficacy <ce:cross-refs id="crfs0040" refid="bib0150 bib0155 bib0160">[30–32]</ce:cross-refs>. Notably, the development of these tools has enabled mechanistic characterization of HTS hits earlier in the drug discovery process, facilitating selection and prioritization of novel and diverse chemotypes with different mechanisms of action for further optimization. Various components of the mechanistic toolbox are listed in <ce:cross-ref id="crf0170" refid="fig0020">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig0020"/></ce:float-anchor>.</ce:para>
                     <ce:para id="par0060" view="all">Affinity parameters that are most ubiquitously characterized as an equilibrium measure of binding are an IC<ce:inf loc="post">50</ce:inf>, a relative parameter depending on assay conditions, as well as <ce:italic>K<ce:inf loc="post">i</ce:inf>
                        </ce:italic> or <ce:italic>K<ce:inf loc="post">d</ce:inf>
                        </ce:italic> which are intrinsic thermodynamic constants. In the case of very tight binding inhibition where K<ce:inf loc="post">i</ce:inf> <<< enzyme concentration, an alternative Morrison titration method can be used to determine inhibitor potency up to 1/100 of enzyme concentration. IC<ce:inf loc="post">50</ce:inf> or <ce:italic>K<ce:inf loc="post">i</ce:inf>
                        </ce:italic> can inform on the binding affinity, but neither can report on the mode of inhibition (MOI), which refers to whether inhibition is competitive, noncompetitive, or uncompetitive with respect to ATP, and has important consequences for selectivity and potency. To assess this important property, we have implemented HT methods to determine MOI incorporating screening of compounds at high and low ATP or with a ATP-competitive HTRF probe, followed by a matrix of ATP/probe and inhibitor concentrations for a more in-depth full-pattern evaluation.</ce:para>
                     <ce:para id="par0065" view="all">Kinetic tools include methods to determine binding mechanism, which provides important insights into kinase–inhibitor interactions <ce:cross-ref id="crf0175" refid="bib0165">[33]</ce:cross-ref>. Here, we monitor inhibitor association kinetics, yielding characteristic plots that can distinguish between different binding mechanisms of one-step, induced fit, or conformational selection, with important consequences for biological efficacy. We have also developed HT methods to measure inhibitor off-rates or residence time (1/<ce:italic>k<ce:inf loc="post">off</ce:inf>
                        </ce:italic>), which has been shown to have a significant effect on both clinical efficacy and safety <ce:cross-refs id="crfs0045" refid="bib0150 bib0160">[30,32]</ce:cross-refs>. Kinetic assays are now routinely carried out for every kinase program. Incorporation of robust global fitting methods has also improved efficient mechanistic data evaluation for large data sets <ce:cross-ref id="crf0180" refid="bib0170">[34]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0070" view="all">
                        <ce:italic>In vitro</ce:italic> to cellular connectivity is a longstanding challenge for kinase inhibitor design, and being able to bridge biochemical–cellular connectivity is vital. Various factors can influence disconnects between these settings, including kinase activation state, variable intracellular ATP, binding partners, and various regulatory mechanisms <ce:cross-ref id="crf0185" refid="bib0175">[35]</ce:cross-ref>. To address this, we have taken various approaches.</ce:para>
                     <ce:para id="par0075" view="all">It has long been recognized that the intracellular concentration of ATP is very different from the concentrations utilized in biochemical enzyme assays <ce:cross-ref id="crf0190" refid="bib0145">[29]</ce:cross-ref>. Notably, it is predicted that the difference in the ATP <ce:italic>K<ce:inf loc="post">m</ce:inf>
                        </ce:italic> of each individual kinase has a significant impact on the enzyme–cell inhibition translation. How do we incorporate this discrepancy into our understanding of translation from enzyme inhibition to cellular function? For example, conducting biochemical analyses at high ATP provides an IC<ce:inf loc="post">50</ce:inf> at a relevant intracellular ATP concentration as a surrogate for cellular ATP. We can also directly profile functional inhibition and target engagement within the same cellular environment using cellular bioluminescence resonance energy transfer (BRET) technology <ce:cross-ref id="crf0195" refid="bib0180">[36]</ce:cross-ref>. Here, we utilize a kinase fused to NanoLuc luciferase and a cell-permeable ATP-competitive small molecule that binds in the active site that is labeled with an acceptor dye (BRET probe), similar in principle to the promiscuous HTRF kinase probes described earlier. Addition of compound can displace the probe leading to a loss in BRET signal, enabling measurement of target engagement. These strategies can provide significant insights into the activity and selectivity of a compound in cellular contexts.</ce:para>
                     <ce:para id="par0080" view="all">The kinome platform evolution described here has fundamentally changed how BMS prosecutes kinase hits-to-leads optimization, and comprises four major tenets: (i) execute weekly in-house SAR/SLR for all kinase programs; (ii) deliver deep hit assessment packages to accelerate early-phase kinase portfolio transitions by integrating compound kinetics and mechanism of action; (iii) engage in continuous improvement to drive panel efficiency, and reduce costs and compound consumption; and (iv) explore novel technologies to expand capabilities. This has resulted in increased capacity and enhanced the speed of delivering high-quality chemical matter and comprehensive data packages to kinase discovery programs, from successful kinase HTS campaigns to lead optimization and mechanism of action studies. Such an interrogation of the kinome demonstrates the intersection of fundamental signaling biology and applied technology, and we believe holds great promise to deliver new inhibitors for the untargeted kinome. Next, we describe case studies highlighting implementation of these platform tools.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0030" view="all">
                  <ce:section-title id="sect0035">Case studies from hits to leads</ce:section-title>
                  <ce:section id="sec0035" view="all">
                     <ce:section-title id="sect0040">Biochemical triage: RIPK3</ce:section-title>
                     <ce:para id="par0085" view="all">Underscoring the importance of mechanistic characterization and diversification of MOA, data from the New Molecular Entities Database show that success in the clinic requires drugs with diverse mechanisms <ce:cross-ref id="crf0200" refid="bib0140">[28]</ce:cross-ref>. Therefore, there is a requirement for HT mechanistic characterization to bin and prioritize hits from HTS into diversified chemotypes earlier in the drug discovery process. To achieve this, we have incorporated HT mechanistic profiling at the HTS confirmation stage. Two important parameters in the triage that enrich the information for chemistry to select diversified chemotypes, are: (i) time dependence to identify potentially slow-binding compounds; and (ii) MOI to determine whether an inhibitor is ATP competitive, uncompetitive, or noncompetitive. This triage process has dramatically changed the paradigm for selection of lead chemotypes to progress in support of hits-to-leads optimization. Receptor-interacting serine/threonine kinase 3 (RIPK3) exemplifies how these methods were applied successfully in a kinase discovery program.</ce:para>
                     <ce:para id="par0090" view="all">RIPK3 kinase has a crucial role in the signaling pathways leading to necroptosis, and is implicated in a variety of disease states <ce:cross-ref id="crf0205" refid="bib0185">[37]</ce:cross-ref>. At the onset of our small-molecule discovery efforts, we focused on identifying differentiated chemotypes from the HTS that target the inactive state of RIPK3 (<ce:cross-ref id="crf0210" refid="fig0025">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig0025"/></ce:float-anchor>a). To successfully implement this strategy, we utilized a full-length construct and a HTRF-binding displacement assay that would be most suitable to identify type II inhibitors that stabilize an inactive conformation <ce:cross-ref id="crf0215" refid="bib0185">[37]</ce:cross-ref>. For time-dependence studies, a complex comprising the kinase, probe, and antibody complex was preformed, to which inhibitor was added to determine a 11-point concentration response curve (CRC) at 5 and 60<ce:hsp sp="0.25"/></ce:hsp>min. A small subset of compounds were identified that might be slow binding; specifically, 44 compounds out of 2571 tested showed a<ce:hsp sp="0.25"/></ce:hsp>≥<ce:hsp sp="0.25"/></ce:hsp>fivefold shift in IC<ce:inf loc="post">50</ce:inf> at 5 and 60<ce:hsp sp="0.25"/></ce:hsp>min (<ce:cross-ref id="crf0220" refid="fig0025">Fig. 5</ce:cross-ref>b). For the MOI studies, use of the HTRF platform allowed for utilization of an ATP-competitive HTRF probe displacement as a tool for the mechanistic studies, specifically IC<ce:inf loc="post">50</ce:inf> shifts between low (1× probe <ce:italic>K<ce:inf loc="post">d</ce:inf>
                        </ce:italic>) and high probe (50× probe <ce:italic>K<ce:inf loc="post">d</ce:inf>
                        </ce:italic>) concentrations were tested. Results using the full set of triaged compounds (2571) revealed a mix of competitive and mixed-type (noncompetitive or uncompetitive) inhibitors, using a IC<ce:inf loc="post">50</ce:inf> shift cut-off of 5 (<ce:cross-ref id="crf0225" refid="fig0025">Fig. 5</ce:cross-ref>c). These studies were then followed up with more in-depth profiling, including residence time kinetics and full pattern mode of inhibition analyses (matrix of probe and inhibitor concentrations).</ce:para>
                     <ce:para id="par0095" view="all">From this analysis, multiple nontraditional kinase chemotypes were identified. We were gratified to identify a known type 2 DFG-out inhibitor from our screening deck (<ce:cross-ref id="crf0230" refid="fig0025">Fig. 5</ce:cross-ref>d), which represented a previously unreported kinase inhibitor type for this target, and which demonstrated remarkable binding potency for RIPK3 along with robust selectivity over RIPK1 and RIPK2. Kinetic evaluation revealed a<ce:hsp sp="0.25"/></ce:hsp>><ce:hsp sp="0.25"/></ce:hsp>sixfold shift in the time-dependence assay with an observed competitive MOI, which could be consistent with a type 2 inhibitor binding mode. Structurally similar compounds from the HTS shared a similar profile.</ce:para>
                     <ce:para id="par0100" view="all">To study an inactive conformation to which a DFG-out inhibitor might bind, a model was constructed based on a RIPK2 DFG-out crystal structure merged with the RIPK3 type I/active conformation crystal structure. This provided a reasonable docking mode for evaluation of these compounds as putative RIPK3 type II inhibitors. Ultimately the type 2 binding mode hypothesis was confirmed by X-ray protein crystallography in a murine kinase domain construct bound with a related scaffold, demonstrating for the first time that RIPK3 can adopt the DFG-out conformation. Notably, RIPK3 Type II inhibitors were found to have improved RIPK family selectivity over their corresponding type I counterparts, and structure-based drug design (SBDD) allowed for further optimization of this series of compounds. In conclusion, the use of mechanistic screening to work up HTS hits led to the identification of a putative type II inhibitor for RIPK3, which was ultimately confirmed by crystallography to adopt a previously unreported DFG-out conformation.</ce:para>
                  </ce:section>
                  <ce:section id="sec0040" view="all">
                     <ce:section-title id="sect0045">Crucial role of inhibitor binding kinetics in lead optimization: TGFβR and BTK</ce:section-title>
                     <ce:para id="par0105" view="all">The importance of binding kinetics is increasingly recognized to have a crucial role, along with steady-state affinity, in determining the cellular potency, <ce:italic>in vivo</ce:italic> efficacy, and safety of a drug <ce:cross-refs id="crfs0050" refid="bib0155 bib0160">[31,32]</ce:cross-refs>. As a consequence, there is a greater demand for inclusion of binding kinetic parameter measurements at earlier stages of drug discovery. It has been suggested that the lifetime of the drug–target complex, the drug residence time, versus just the binding affinity, dictate much of the <ce:italic>in vivo</ce:italic> pharmacological activity <ce:cross-refs id="crfs0055" refid="bib0150 bib0190">[30,38]</ce:cross-refs>. In an <ce:italic>in vitro</ce:italic> system, compounds are measured under fixed concentrations at thermodynamic equilibria. This likely overestimates the drug potency because it does not accurately mimic an <ce:italic>in vivo</ce:italic> open system where drug concentration fluctuates with time. Long residence time can also effectively sequester the drug, reducing the potential for off-target interactions and mitigating toxicity, especially in the case where the resynthesis rate of the kinase is slow leading to extended PD effects. However, shorter drug residence time might also be advantageous in minimizing mechanism-based toxicity because it can lead to a greater balance in mass-action competition between the drug and endogenous ligands. These outcomes do not need to be considered as mutually exclusive, and an optimal residence time will be both target specific and context dependent.</ce:para>
                     <ce:para id="par0110" view="all">To guide our lead optimization process, we have developed HTRF methods for rapid determination of kinase–inhibitor association and dissociation rates in a plate-based format. Application of these methods to several kinase targets has provided important insights to help predict binding mode, suggest the molecular basis for selectivity, aid in inhibitor design, prioritize compounds for crystallography, provide a filter for cell based assays, and bin compounds for PK/PD studies.</ce:para>
                     <ce:para id="par0115" view="all">An example from the transforming growth factor beta receptor 1 (TGFβR1) kinase program highlights key impacts of optimizing inhibitor residence time and half-life of the kinase–inhibitor complex in lead optimization. For TGFβR1, a transmembrane serine threonine kinase involved in signal transduction in the TGFβ canonical pathway, kinetic profiling of leads together with structural analysis allowed us to build a structure–kinetic relationship model (SKR) <ce:cross-ref id="crf0235" refid="bib0195">[39]</ce:cross-ref>. For the lead pyrrolotriazine chemotype (Compound <ce:bold>2</ce:bold>) in <ce:cross-ref id="crf0240" refid="fig0030">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig0030"/></ce:float-anchor>, this analysis highlighted the potential impact of an energetically favorable hydrogen-bond interaction with Asp 351. Thus, we replaced a CH at the 7-position of the pyrrolotriazine with a NH hydrogen bond donor (Compound <ce:bold>3</ce:bold>) and, as predicted by the SKR model, this resulted in improved binding affinities and long residence times in the TGFβR1-binding pocket (T<ce:inf loc="post">1/2</ce:inf> >120<ce:hsp sp="0.25"/></ce:hsp>min). Notably, this also translated to superior potency in cellular assays, including in primary human T cells. Consistent with the longer duration of target engagement, Compound <ce:bold>3</ce:bold> also had robust activity in PD studies in a mouse carcinoma model. By contrast, Compound <ce:bold>1</ce:bold>, which lacks this key hydrogen bond, showed a significantly shorter residence time and also significantly weaker cell potency. Efforts to design chemotypes that leverage hydrogen bonding with Asp351, thereby increasing residence time and improving cellular potency without compromising on physicochemical properties, are in progress.</ce:para>
                     <ce:para id="par0120" view="all">The limiting case of a long residence time compound is a covalent inhibitor, which provides various opportunities for complete pharmacological inhibition of the target, prolonged effects beyond drug clearance, and the potential to reduce drug exposure, as well as an improved selectivity profile. By contrast, some of the biggest risks for irreversibles are potential toxicities because of nonspecific covalent binding. This requires a careful balance between binding affinity of the core and reactivity of the electrophile. To support the discovery of an irreversible inhibitor for BTK <ce:cross-refs id="crfs0060" refid="bib0200 bib0205">[40,41]</ce:cross-refs>, we needed to go beyond equilibrium IC<ce:inf loc="post">50</ce:inf> measurements, which do not accurately capture the potency of an irreversible inhibitor. This is illustrated in <ce:cross-ref id="crf0245" refid="fig0035">Fig. 7</ce:cross-ref>
                        <ce:float-anchor refid="fig0035"/></ce:float-anchor>a, showing the time-dependent inactivation reaction scheme.</ce:para>
                     <ce:para id="par0125" view="all">The first step involves reversible complex formation to the active site of Bruton's tyrosine kinase (BTK) to establish [E·I] as measured by <ce:italic>K<ce:inf loc="post">i</ce:inf>
                        </ce:italic>, followed by a bond-forming inactivation step of an electrophilic center on the inhibitor with the nucleophilic Cys481 residue in the active site, resulting in complete enzyme inactivation [EI], as measured by <ce:italic>k<ce:inf loc="post">inact</ce:inf>
                        </ce:italic>. The second order rate of inactivation represented by <ce:italic>k<ce:inf loc="post">inact</ce:inf>
                        </ce:italic>/<ce:italic>Ki</ce:italic> captures the potency of an irreversible inhibitor, and can be used to tune the balance between <ce:italic>k<ce:inf loc="post">inact</ce:inf>
                        </ce:italic> and <ce:italic>Ki</ce:italic> to optimize both geometry of core and reactivity of the electrophile. Accordingly, we developed a BTK inactivation kinetics assay (<ce:cross-ref id="crf0250" refid="fig0035">Fig. 7</ce:cross-ref>b). This allowed us to dissect the contribution of binding affinity of the reversible core and reactivity of the linker warhead to the potency, and enable medicinal chemistry optimization efforts. Profiling demonstrated that, although equilibrium IC<ce:inf loc="post">50</ce:inf>s for the marketed BTK irreversible inhibitor ibrutinib (Compound <ce:bold>4</ce:bold>) and the BMS lead branebrutinib (Compound <ce:bold>5</ce:bold>) were similar, there were differences in the <ce:italic>k<ce:inf loc="post">inact</ce:inf>
                        </ce:italic> and <ce:italic>K<ce:inf loc="post">i</ce:inf>
                        </ce:italic> values, demonstrating that tighter binding of the core allows the use of a less reactive electrophile, potentially mitigating off-target effects while still maintaining BTK potency. This compound, currently in Phase II clinical trials, has potential to be best in class for autoimmune disease because of its low human dose and overall selectivity profile <ce:cross-ref id="crf0255" refid="bib0205">[41]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0045" view="all">
                     <ce:section-title id="sect0050">Bringing it full circle: chemogenomics screen to the clinic: TYK2</ce:section-title>
                     <ce:para id="par0130" view="all">In the case of targeting tyrosine kinase 2 (TYK2), the key challenge was achieving high selectivity over the other JAK family kinases (JAK1, 2, and3). Initial efforts targeting the JH1 kinase domain with a type I inhibitor failed to achieve the desired selectivity profile. This led to an effort to identify selective, allosteric modulators via a novel chemogenomics approach that combined a cell-based reporter assay in parallel with <ce:italic>in vitro</ce:italic> kinome-wide profiling. Deconvolution of the hits from this screen identified an allosteric inhibitor that bound to the JH2 pseudokinase domain of TYK2, apparently stabilizing an inactive conformation of the kinase catalytic domain <ce:cross-ref id="crf0260" refid="bib0210">[42]</ce:cross-ref>. The JH2 pseudokinase domain at the C terminus of the protein precedes the catalytically active JH1 kinase domain, and contains several key residue differences from the TYK2 and JAK JH1 domains, enabling high selectivity and potency to be achieved <ce:cross-refs id="crfs0065" refid="bib0215 bib0220">[43,44]</ce:cross-refs> (<ce:cross-ref id="crf0265" refid="fig0040">Fig. 8</ce:cross-ref>
                        <ce:float-anchor refid="fig0040"/></ce:float-anchor>a). This class of allosteric inhibitors was shown to be highly specific for binding to TYK2 JH2 without significant binding affinity in the canonical TYK2, JAK1, JAK2, and JAK3 JH1 catalytic domains (<ce:cross-ref id="crf0270" refid="fig0040">Fig. 8</ce:cross-ref>b). Evidence suggests that Compound <ce:bold>7</ce:bold> binds to the JH2 domain of TYK2 and stabilizes an autoinhibitory JH2 interaction with the catalytic JH1 domain, preventing catalytic activity of the kinase JH1 domain <ce:cross-ref id="crf0275" refid="bib0210">[42]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0135" view="all">The underlying mechanism of action was confirmed by isothermal titration calorimetry (ITC) and kinase binding assays [scintillation proximity assays (SPAs) and HTRF] to the isolated JH1 and/or JH2 domain. During optimization, efforts became concentrated on improving potency while maintaining the selectivity profile, requiring the development of binding assays capable of detecting highly potent compounds. To enable this, we developed a sensitive HT HTRF method utilizing binding displacement in conjunction with a Morrison fitting method for tight binding behavior, known as the Morrison equation <ce:cross-ref id="crf0280" refid="bib0225">[45]</ce:cross-ref>. A notable strength of the HTRF binding platform is that it enables study of inhibitors that target noncatalytically active kinases (i.e., pseudokinase as well as inactive kinase states). This approach was used to differentiate potent JH2 binders (nM–pM affinity) and help drive SAR towards improved functional potency in cellular [interferon (IFN)-α] and human whole-blood assays (<ce:cross-ref id="crf0285" refid="fig0040">Fig. 8</ce:cross-ref>c).</ce:para>
                     <ce:para id="par0140" view="all">These assays coupled with X-ray crystallography reveal a complete picture of the structural basis for selectivity and potency <ce:cross-ref id="crf0290" refid="bib0220">[44]</ce:cross-ref> (<ce:cross-ref id="crf0295" refid="fig0040">Fig. 8</ce:cross-ref>d) for this allosteric inhibitor, which binds to the regulatory TYK2 JH2 pseudokinase domain (PKD) distal from the kinase active site. Compound <ce:bold>7</ce:bold> was designed to occupy a shallow lipophilic pocket created by a rare alanine residue 961 (‘alanine pocket’) in the ligand-binding pocket of the PKD, which imparts a high level of selectivity by incorporating a crucial methyl amide group that is sterically blocked in most kinase catalytic sites. Potency is further driven by optimized hydrogen bonding to the ‘hinge region’ of the JH2 domain and additional potency was gained by displacement of an energetically unfavorable water molecule in the binding site ‘front pocket’ by a methoxy group and the triazole moiety. Currently, compound <ce:bold>7</ce:bold> is in Phase III clinical trials.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0050" view="all">
                  <ce:section-title id="sect0055">Concluding remarks and outlook</ce:section-title>
                  <ce:para id="par0145" view="all">The increased molecular level understanding of kinase cellular signaling cascades, innovation in preclinical target validation, and advances in medicinal chemistry, coupled with growth in kinase assay technologies, all bode well for the future of kinase drug discovery <ce:cross-ref id="crf0300" refid="bib0005">[1]</ce:cross-ref>. This is further supported by the expansion of clinical pipelines across the industry to include other disease areas beyond oncology, such as fibrosis, immunology, and cardiovascular disease. To address the needs of increasingly complex kinase targets and emerging biology, a comprehensive kinome platform has been built at BMS that provides parallel selectivity profiling and mechanism-of-action studies to rapidly drive rapid compound progression. This comprises a diverse set of screening, profiling, and mechanistic tools and technologies to address unique program needs and challenges across various pharmacological profiles. Key data deliverables for characterization of enzyme–inhibitor mechanisms include affinity and MOI determination as well as binding kinetics characterization. Such mechanistic readouts and assay tools are essential to deliver the best and first-in-class kinase drug candidates, enabling informed selection of different kinase inhibitor types through mechanistic profiling at an early stage, and later enabling in-depth characterization of mode of action during lead optimization. Leveraging this kinase hits-to-leads platform has enabled identification and characterization of all inhibitor types, inclusive of allosteric and irreversible kinase inhibitors, and can also be applied to proteolysis targeting chimeras (PROTACs) in targeted protein degradation. Significantly, these platforms were crucial in supporting efforts toward the discovery and optimization of both pseudokinase-directed allosteric TYK2 and irreversible BTK inhibitors.</ce:para>
                  <ce:para id="par0150" view="all">Several key learnings have emerged from three decades of kinase drug discovery: (i) all inhibitor types should be considered when prosecuting a kinase program because the benefits and challenges associated with each inhibitor type depend on the specific biology of each target; (ii) targeting kinases with more selective small-molecule inhibitors might be better addressed by exploring type III/IV inhibitors; (iii) mechanistic tools are central for a deeper understanding of inhibitor MOA to drive efficacy and safety and deliver first and best-in-class kinase drug candidates; (iv) incorporation of structure into the optimization process enables the development of SARs and SKRs that inform ligand design; and (v) a flexible platform is required with both binding and catalytic activity formats to support the discovery and optimization of all inhibitor types.</ce:para>
                  <ce:para id="par0155" view="all">Technology evolution must also be a cornerstone of a leading platform strategy as the kinase field continues to expand into new target space. Accordingly, we continue to evolve our platform in multiple dimensions. For example, internal kinome profiling has enabled the generation of large kinase data sets, which together with ‘omics data (proteomic and genomic), provide novel opportunities to apply machine-learning techniques to predict inhibitor efficacy and off-target liability, decipher signaling interaction networks for target deconvolution, and to find new targets associated with a disease phenotype <ce:cross-ref id="crf0305" refid="bib0230">[46]</ce:cross-ref>. Moving forward, expansion to include innovative strategies that incorporate kinase inhibitor conformational signatures into the screening paradigm <ce:cross-ref id="crf0310" refid="bib0235">[47]</ce:cross-ref>, novel assays to enable kinase activity measurements, and pathway screening in more physiologically relevant cell backgrounds <ce:cross-ref id="crf0315" refid="bib0175">[35]</ce:cross-ref>, as well as incorporation of new modalities, such as PROTACS for targeted protein degradation of intractable kinases <ce:cross-ref id="crf0320" refid="bib0240">[48]</ce:cross-ref>, provide promising areas for growth and new pharmacology. Breakthroughs in technology and experimental capabilities in all of these areas will bring many opportunities for developing novel kinase therapies and drug candidates.</ce:para>
               </ce:section>
               <ce:section id="sec0055" view="all">
                  <ce:section-title id="sect0060">Declaration of interests</ce:section-title>
                  <ce:para id="par0160" view="all">The authors declare no competing financial interest.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0005" view="all">
               <ce:section-title id="sect0065">Acknowledgments</ce:section-title>
               <ce:para id="par0165" view="all">We would like to thank Amy Hart, Steve Wrobleski, Scott Watterson, and Ryan Moslin for critical reading of the manuscript. Special thanks to Julia Heinrich for kinase patent literature search support, Mingyi Liu for bioinformatic support, Ramesh Padmanabha for kinome panel quality control, Gretchen Schroeder for initial probe synthesis, and Hao Lu and Lynn Abell for contributions to hit triage toolbox and kinetics toolbox. Special thanks to the kinase working groups, as well as the kinome, cellular technologies, and data management and analytics teams for assay and data support.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="bibl0005" view="all">
               <ce:section-title id="sect0070">References</ce:section-title>
               <ce:bibliography-sec id="bibs0005" view="all">
                  <ce:bib-reference id="bib0005">
                     <ce:label>1</ce:label>
                     <sb:reference id="sbref0005">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.M.</ce:given-name>
                                 <ce:surname>Ferguson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinase inhibitors: the road ahead</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>353</sb:first-page>
                              <sb:last-page>377</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0010">
                     <ce:label>2</ce:label>
                     <sb:reference id="sbref0010">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Roskoski</ce:surname>
                                 <ce:suffix>Jr</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Properties of FDA-approved small molecule protein kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>144</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>19</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0015">
                     <ce:label>3</ce:label>
                     <sb:reference id="sbref0015">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Nagar</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4236</sb:first-page>
                              <sb:last-page>4243</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0020">
                     <ce:label>4</ce:label>
                     <sb:reference id="sbref0020">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nakano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Omura</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Antibiot.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>17</sb:first-page>
                              <sb:last-page>26</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0025">
                     <ce:label>5</ce:label>
                     <sb:reference id="sbref0025">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>217</sb:first-page>
                              <sb:last-page>227</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0030">
                     <ce:label>6</ce:label>
                     <sb:reference id="sbref0030">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Takeuchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ito</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Receptor tyrosine kinases and targeted cancer therapeutics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biol. Pharm. Bull.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1774</sb:first-page>
                              <sb:last-page>1780</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0035">
                     <ce:label>7</ce:label>
                     <sb:reference id="sbref0035">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Traynor</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FDA approves tofacitinib for rheumatoid arthritis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. J. Health Syst. Pharm.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>69</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2120</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0040">
                     <ce:label>8</ce:label>
                     <sb:reference id="sbref0040">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FDA-approved small-molecule kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>422</sb:first-page>
                              <sb:last-page>439</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0045">
                     <ce:label>9</ce:label>
                     <sb:reference id="sbref0045">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinase drug discovery--what’s next in the field?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>96</sb:first-page>
                              <sb:last-page>104</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0050">
                     <ce:label>10</ce:label>
                     <sb:reference id="sbref0050">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Ficarro</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphoproteome analysis by mass spectrometry and its application to <ce:italic>Saccharomyces cerevisiae</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>301</sb:first-page>
                              <sb:last-page>305</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0055">
                     <ce:label>11</ce:label>
                     <sb:reference id="sbref0055">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecularly targeted cancer therapy: some lessons from the past decade</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0060">
                     <ce:label>12</ce:label>
                     <sb:reference id="sbref0060">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Adjei</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel agents on the horizon for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>CA Cancer J. Clin.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>111</sb:first-page>
                              <sb:last-page>137</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0065">
                     <ce:label>13</ce:label>
                     <sb:reference id="sbref0065">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bernards</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Biochem. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>39</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>465</sb:first-page>
                              <sb:last-page>474</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0070">
                     <ce:label>14</ce:label>
                     <sb:reference id="sbref0070">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Davis</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comprehensive analysis of kinase inhibitor selectivity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1046</sb:first-page>
                              <sb:last-page>1051</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0075">
                     <ce:label>15</ce:label>
                     <sb:reference id="sbref0075">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Manning</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The protein kinase complement of the human genome</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>298</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1912</sb:first-page>
                              <sb:last-page>1934</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0080">
                     <ce:label>16</ce:label>
                     <sb:reference id="sbref0080">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Knighton</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>253</sb:volume-nr>
                              </sb:series>
                              <sb:date>1991</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>407</sb:first-page>
                              <sb:last-page>414</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0085">
                     <ce:label>17</ce:label>
                     <sb:reference id="sbref0085">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Seeliger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting conformational plasticity of protein kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>190</sb:first-page>
                              <sb:last-page>200</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0090">
                     <ce:label>18</ce:label>
                     <sb:reference id="sbref0090">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Cowan-Jacob</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Future Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>541</sb:first-page>
                              <sb:last-page>561</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0095">
                     <ce:label>19</ce:label>
                     <sb:reference id="sbref0095">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Future Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>29</sb:first-page>
                              <sb:last-page>43</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0100">
                     <ce:label>20</ce:label>
                     <sb:reference id="sbref0100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinase profiling assays: a technology review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov. Today Technol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>8</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0105">
                     <ce:label>21</ce:label>
                     <sb:reference id="sbref0105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.W.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anal. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>269</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>94</sb:first-page>
                              <sb:last-page>104</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0110">
                     <ce:label>22</ce:label>
                     <sb:reference id="sbref0110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb (2004-2009)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov. Today</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>733</sb:first-page>
                              <sb:last-page>740</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0115">
                     <ce:label>23</ce:label>
                     <sb:reference id="sbref0115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Levitzki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinase inhibitors as a therapeutic modality</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acc Chem. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>462</sb:first-page>
                              <sb:last-page>469</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0120">
                     <ce:label>24</ce:label>
                     <sb:reference id="sbref0120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Muller</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The ins and outs of selective kinase inhibitor development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>818</sb:first-page>
                              <sb:last-page>821</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0125">
                     <ce:label>25</ce:label>
                     <sb:reference id="sbref0125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Degorce</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>HTRF: a technology tailored for drug discovery - a review of theoretical aspects and recent applications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Chem. Genomics</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>22</sb:first-page>
                              <sb:last-page>32</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0130">
                     <ce:label>26</ce:label>
                     <sb:reference id="sbref0130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Branca</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multi-kinase inhibitors create buzz at ASCO</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>639</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0135">
                     <ce:label>27</ce:label>
                     <sb:reference id="sbref0135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Swinney</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biochemical mechanisms of drug action: what does it take for success?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>801</sb:first-page>
                              <sb:last-page>808</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0140">
                     <ce:label>28</ce:label>
                     <sb:reference id="sbref0140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Swinney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Anthony</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>How were new medicines discovered?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>507</sb:first-page>
                              <sb:last-page>519</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0145">
                     <ce:label>29</ce:label>
                     <sb:reference id="sbref0145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.A.</ce:given-name>
                                 <ce:surname>Knight</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Shokat</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Features of selective kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>621</sb:first-page>
                              <sb:last-page>637</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0150">
                     <ce:label>30</ce:label>
                     <sb:reference id="sbref0150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Copeland</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The drug-target residence time model: a 10-year retrospective</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>87</sb:first-page>
                              <sb:last-page>95</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0155">
                     <ce:label>31</ce:label>
                     <sb:reference id="sbref0155">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Copeland</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Drug-target residence time and its implications for lead optimization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>730</sb:first-page>
                              <sb:last-page>739</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0160">
                     <ce:label>32</ce:label>
                     <sb:reference id="sbref0160">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Monsma</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The importance of drug-target residence time</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Drug Discov. Devel.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>488</sb:first-page>
                              <sb:last-page>496</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0165">
                     <ce:label>33</ce:label>
                     <sb:reference id="sbref0165">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Tummino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Copeland</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Residence time of receptor-ligand complexes and its effect on biological function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochemistry</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5481</sb:first-page>
                              <sb:last-page>5492</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0170">
                     <ce:label>34</ce:label>
                     <sb:reference id="sbref0170">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>High performance enzyme kinetics of turnover, activation and inhibition for translational drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>17</sb:first-page>
                              <sb:last-page>37</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0175">
                     <ce:label>35</ce:label>
                     <sb:reference id="sbref0175">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Vasta</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Quantitative, wide-spectrum kinase profiling in live cells for assessing the effect of cellular ATP on target engagement</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>206</sb:first-page>
                              <sb:last-page>214</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0180">
                     <ce:label>36</ce:label>
                     <sb:reference id="sbref0180">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Robers</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Target engagement and drug residence time can be observed in living cells with BRET</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10091</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0185">
                     <ce:label>37</ce:label>
                     <sb:reference id="sbref0185">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Hart</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of RIPK3 type II inhibitors using high-throughput mechanistic studies in hit triage</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>266</sb:first-page>
                              <sb:last-page>271</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0190">
                     <ce:label>38</ce:label>
                     <sb:reference id="sbref0190">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Tonge</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Drug-target residence time: critical information for lead optimization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>467</sb:first-page>
                              <sb:last-page>474</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0195">
                     <ce:label>39</ce:label>
                     <sb:reference id="sbref0195">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.S.</ce:given-name>
                                 <ce:surname>Harikrishnan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFbetaRI)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1026</sb:first-page>
                              <sb:last-page>1034</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0200">
                     <ce:label>40</ce:label>
                     <sb:reference id="sbref0200">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Watterson</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 6-fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8- carboxamide (BMS-986142): a reversible inhibitor of Bruton’s Tyrosine Kinase (BTK) conformationally constrained by two locked atropisomers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9173</sb:first-page>
                              <sb:last-page>9200</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0205">
                     <ce:label>41</ce:label>
                     <sb:reference id="sbref0205">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Watterson</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of branebrutinib (BMS-986195): a strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of Bruton’s tyrosine kinase (BTK)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3228</sb:first-page>
                              <sb:last-page>3250</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0210">
                     <ce:label>42</ce:label>
                     <sb:reference id="sbref0210">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Tokarski</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>290</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11061</sb:first-page>
                              <sb:last-page>11174</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0215">
                     <ce:label>43</ce:label>
                     <sb:reference id="sbref0215">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moslin</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of N-methyl nicotinamide and N-methyl pyridazine-3-carboxamide pseudokinase domain ligands as highly selective allosteric inhibitors of tyrosine kinase 2 (TYK2)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8953</sb:first-page>
                              <sb:last-page>8972</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0220">
                     <ce:label>44</ce:label>
                     <sb:reference id="sbref0220">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Wrobleski</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8973</sb:first-page>
                              <sb:last-page>8995</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0225">
                     <ce:label>45</ce:label>
                     <sb:reference id="sbref0225">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Murphy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Determination of accurate Ki values for tight-binding enzyme inhibitors: an in silico study for experimental error and assay design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Analyt. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>327</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>61</sb:first-page>
                              <sb:last-page>67</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0230">
                     <ce:label>46</ce:label>
                     <sb:reference id="sbref0230">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bitencourt-Ferreira</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Application of machine learning techniques to predict binding affinity for drug targets. a study of cyclin-dependent kinase 2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>253</sb:first-page>
                              <sb:last-page>265</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0235">
                     <ce:label>47</ce:label>
                     <sb:reference id="sbref0235">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Young</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Second-Harmonic Generation (SHG) for conformational measurements: assay development, optimization, and screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Methods Enzymol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>610</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>167</sb:first-page>
                              <sb:last-page>190</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0240">
                     <ce:label>48</ce:label>
                     <sb:reference id="sbref0240">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Schapira</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeted protein degradation: expanding the toolbox</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>949</sb:first-page>
                              <sb:last-page>963</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
            <ce:biography id="vt0005" view="all">
               <ce:link xlink:href="pii:S1359644621000489/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" locator="fx1"/></ce:link>
               <ce:simple-para id="spar0055" view="all">
                  <ce:bold>Charu Chaudhry</ce:bold> leads the Kinase Mechanistic Team within the Leads Discovery and Optimization group at Bristol Myers Squibb (BMS), delivering in-depth mechanistic profiling of small-molecule kinase inhibitors in the hits-to-lead and lead optimization stages of drug discovery programs across the entire R&D portfolio. Her team utilizes multidisciplinary approaches in biochemistry/biophysics, enzymology, and molecular and cellular pharmacology. Her research interests broadly encompass structure–function relationships, the role of mechanism in drug discovery, and the adoption and implementation of innovative technologies. Charu received her BS in Chemistry from Massachusetts Institute of Technology and her PhD in Molecular Biophysics and Biochemistry from Yale University.</ce:simple-para>
            </ce:biography>
            <ce:biography id="vt0010" view="all">
               <ce:link xlink:href="pii:S1359644621000489/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" locator="fx2"/></ce:link>
               <ce:simple-para id="spar0060" view="all">
                  <ce:bold>Jonathan Lippy</ce:bold> is Director of Compound Management and Core Automation within the Leads Discovery & Optimization group at BMS. He also leads the Kinome Hits-to-Leads team, which provides just-in-time structural activity and liability assessments, and mechanism and data analytics support for the BMS Kinase Discovery portfolio. Jonathan has 23 years’ drug discovery experience in lead optimization, high-throughput screening, mechanistic biochemistry and pharmacology across kinases, G-protein-coupled receptors, nuclear hormone receptors and enzyme target classes. He was responsible for leading a 3-year infrastructure strategy resulting in the conversion of in-house automation systems to commercial state-of-the-art automation capabilities at BMS with reduced footprint and increased capabilities across multimodalities.</ce:simple-para>
            </ce:biography>
            <ce:biography id="vt0015" view="all">
               <ce:link xlink:href="pii:S1359644621000489/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" locator="fx3"/></ce:link>
               <ce:simple-para id="spar0065" view="all">
                  <ce:bold>Litao Zhang</ce:bold>, Vice President of Leads Discovery and Optimization at BMS, has developed broad scientific expertise in multiple disease areas over the past two decades. Litao spearheaded efforts to put in place first-in-class technology platforms and informatics solutions leading to a significant paradigm shift that repositioned BMS technology infrastructure at the frontier of two major drug target classes, kinases and G-protein-coupled receptors. She also identified technology gaps in each of the therapeutic areas, enabling advanced technology solutions and translational <ce:italic>in vitro</ce:italic> cellular models for high-throughput screening to advance discovery programs from concept to drug candidate nomination. As a result, her team has impacted over >100 drug candidate nominations. She is currently the Global Head of Discovery Technologies and Molecular Pharmacology at Janssen.</ce:simple-para>
            </ce:biography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>